Penserra Capital Management’s Definium Therapeutics DFTX Stock Holding History

Penserra Capital Management’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$64K	Buy	+1,370	New	+$33.9K	﹤0.01%	789
2022 Q3	–	Sell	-29,458	Closed	-$282K	–	1116
2022 Q2	$282K	Sell	29,458 -2,599	-8%	-$32.9K	0.01%	590
2022 Q1	$442K	Buy	32,057 +15,916	+99%	+$276K	0.01%	519
2021 Q4	$334K	Buy	16,141 +3,073	+24%	+$98.1K	0.01%	577
2021 Q3	$456K	Buy	13,068 +4,841	+59%	+$209K	0.01%	522
2021 Q2	$425K	Buy	+8,227	New	+$432K	0.01%	534

Other funds holding DFTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Penserra Capital Management's DFTX Position: Q2 2026 in Review

Penserra Capital Management opened a new position in Definium Therapeutics (DFTX) in Q2 2026: 1,370 shares worth $64K. The stake represents ﹤0.01% of the portfolio and ranks #789 among its holdings. This is a return to the name: Penserra Capital Management previously reported a position in DFTX as recently as Q2 2022.

Penserra Capital Management first reported a position in DFTX in Q2 2021 and has held it in 6 quarters since. The position peaked at $456K in Q3 2021. 362 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

Penserra Capital Management held 1,370 shares of Definium Therapeutics worth $64K as of Q2 2026.
Definium Therapeutics was a new Penserra Capital Management position in Q2 2026.
Definium Therapeutics made up ﹤0.01% of Penserra Capital Management's portfolio in Q2 2026, its #789 holding.
Penserra Capital Management first reported a position in Definium Therapeutics in Q2 2021 and has held it in 6 quarters since.
Penserra Capital Management's Definium Therapeutics position peaked at $456K in Q3 2021.
362 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Penserra Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.